Trials
1 active
3 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Sclerosing Cholangitis
- Main trialPhase 3
- “Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis”In the company’s words, NCT06886360 on ClinicalTrials.gov
- Other names
- norUrsodeoxycholic acid · norUDCA · NCA · NUC
Other drugs for Primary Sclerosing Cholangitis
- ElafibranorIpsen · Phase 3
- MaralixibatMirum Pharmaceuticals, Inc. · Phase 3
- LB-P8LISCure Biosciences · Phase 2
- HK-660SCuromeBiosciences · Phase 2
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
- TAK-781Takeda · Phase 1
Coming up1
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Sep 2027 | Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) | |
| Phase 3Unknown | Jan 2025 | norUrsodeoxycholic Acid vs Placebo in PSC | |
| Phase 2Unknown | Jan 2025 | Norursodeoxycholic Acid vs. Placebo in NASH |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026